{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:49:34Z","timestamp":1793717374731,"version":"4.6.1"},"reference-count":35,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013638\/1"],"award-info":[{"award-number":["MR\/N013638\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["IMPALA (project reference 16\/136\/35)"],"award-info":[{"award-number":["IMPALA (project reference 16\/136\/35)"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005850","name":"International Union Against Tuberculosis and Lung Disease","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/0170"],"award-info":[{"award-number":["PI17\/0170"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7\/2007-2013, ERC grant agreement number 668954"],"award-info":[{"award-number":["FP7\/2007-2013, ERC grant agreement number 668954"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,1,19]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>There have been no worldwide standardised surveys of prevalence and severity of asthma, rhinoconjunctivitis and eczema in school children for 15\u2005years. The present study aims to provide this information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following the exact International Study of Asthma and Allergies in Childhood (ISAAC) methodology (cross-sectional questionnaire-based survey), Global Asthma Network (GAN) Phase I was carried out between 2015 and 2020 in many centres worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 157\u200a784 adolescents (13\u201314\u2005years of age) in 63 centres in 25 countries and 101\u200a777 children (6\u20137\u2005years of age) in 44 centres in 16 countries. The current prevalence of symptoms, respectively, was 11.0% and 9.1% for asthma, 13.3% and 7.7% for rhinoconjunctivitis and 6.4% and 5.9% for eczema. The prevalence of asthma ever was 10.5% and 7.6%, hay fever ever was 15.2% and 11.1% and eczema ever was 10.6% and 13.4%, respectively. Centres in low or lower middle gross national income countries (LICs or LMICs) had significantly lower prevalence of the three disease symptoms and diagnoses (except for hay fever). In children, the prevalence of asthma and rhinoconjunctivitis symptoms was higher in boys, while the reverse occurred among adolescents. For eczema, while the prevalence among female adolescents was double that of males, there was no sex difference among children. Centre accounted for non-negligible variability in all disease symptoms (10\u201320%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The burdens of asthma, rhinoconjunctivitis and eczema vary widely among the limited number of countries studied. Although symptom prevalence is lower in LICs and LMICs, it represents a considerable burden everywhere studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.02866-2021","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T14:10:14Z","timestamp":1644502214000},"page":"2102866","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":207,"title":["The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study"],"prefix":"10.1183","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0925-3851","authenticated-orcid":false,"given":"Luis","family":"Garc\u00eda-Marcos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1768-3832","authenticated-orcid":false,"given":"M. Innes","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-6619","authenticated-orcid":false,"given":"Eamon","family":"Ellwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bissell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-2490","authenticated-orcid":false,"given":"Chen-Yuan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-8862","authenticated-orcid":false,"given":"Asma","family":"El Sony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4023","authenticated-orcid":false,"given":"Philippa","family":"Ellwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8976-8053","authenticated-orcid":false,"given":"Guy B.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Elena","family":"Mart\u00ednez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-3055","authenticated-orcid":false,"given":"Virginia","family":"Perez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-1194","authenticated-orcid":false,"given":"Richard J.","family":"Silverwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Strachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"2026061109252054000_60.3.2102866.1","unstructured":"Asher MI , Ellwood P , Gilchrist C , et al. The Global Asthma Report 2018. Auckland, New Zealand, The Global Asthma Network , 2018."},{"key":"2026061109252054000_60.3.2102866.2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0140-6736(21)00458-X","article-title":"Improving lung health in low-income and middle-income countries: from challenges to solutions","volume":"397","author":"Meghji","year":"2021","journal-title":"Lancet"},{"key":"2026061109252054000_60.3.2102866.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03179-2021"},{"key":"2026061109252054000_60.3.2102866.4","unstructured":"Global Burden of Disease 2019. https:\/\/vizhub.healthdata.org\/gbd-compare\/ Date last accessed: November 13, 2021."},{"key":"2026061109252054000_60.3.2102866.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.106609"},{"key":"2026061109252054000_60.3.2102866.6","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division . World Population Prospects: The 2019 Revision. 2021. Available from: https:\/\/population.un.org\/wpp\/"},{"key":"2026061109252054000_60.3.2102866.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01450-1"},{"key":"2026061109252054000_60.3.2102866.8","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.3013"},{"key":"2026061109252054000_60.3.2102866.9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jaci.2020.12.001","article-title":"Atopic eczema in adulthood and mortality: UK population-based cohort study, 1998\u20132016","volume":"147","author":"Silverwood","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026061109252054000_60.3.2102866.10","doi-asserted-by":"crossref","first-page":"e13656","DOI":"10.1111\/pai.13656","article-title":"Worldwide time trends in prevalence of symptoms of rhinoconjunctivitis in children: Global Asthma Network Phase I","volume":"33","author":"Strachan","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"2026061109252054000_60.3.2102866.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01884.x"},{"key":"2026061109252054000_60.3.2102866.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.009"},{"key":"2026061109252054000_60.3.2102866.13","doi-asserted-by":"crossref","first-page":"1601605","DOI":"10.1183\/13993003.01605-2016","article-title":"The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors","volume":"49","author":"Ellwood","year":"2017","journal-title":"Eur Respir J"},{"key":"2026061109252054000_60.3.2102866.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00041403"},{"key":"2026061109252054000_60.3.2102866.15","first-page":"1174","article-title":"Translation of questions: the International Study of Asthma and Allergies in Childhood (ISAAC) experience","volume":"13","author":"Ellwood","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026061109252054000_60.3.2102866.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.95.08030483"},{"key":"2026061109252054000_60.3.2102866.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12020315"},{"key":"2026061109252054000_60.3.2102866.18","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.3390\/jcm9113688","article-title":"Global Asthma Network Phase I surveillance: geographical coverage and response rates","volume":"9","author":"Ellwood","year":"2020","journal-title":"J Clin Med"},{"key":"2026061109252054000_60.3.2102866.19","first-page":"10","article-title":"The International Study of Asthma and Allergies in Childhood (ISAAC): Phase Three rationale and methods","volume":"9","author":"Ellwood","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026061109252054000_60.3.2102866.20","unstructured":"Hamadeh N , Van Rompaey C , Metreau E . 2020. New World Bank Country Classifications by Income Level: 2021\u20132022. https:\/\/blogs.worldbank.org\/opendata\/new-world-bank-countryclassifications-income-level-2021-2022 Date last accessed: July 1, 2022."},{"key":"2026061109252054000_60.3.2102866.21","first-page":"1059","article-title":"The impact of the method of consent on response rates in the ISAAC time trends study","volume":"14","author":"Ellwood","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026061109252054000_60.3.2102866.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07302-9"},{"key":"2026061109252054000_60.3.2102866.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69283-0"},{"key":"2026061109252054000_60.3.2102866.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2012.03.001"},{"key":"2026061109252054000_60.3.2102866.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007302"},{"key":"2026061109252054000_60.3.2102866.26","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3829"},{"key":"2026061109252054000_60.3.2102866.27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200607-994OC"},{"key":"2026061109252054000_60.3.2102866.28","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.5415\/apallergy.2018.8.e7","article-title":"The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions","volume":"8","author":"Passali","year":"2018","journal-title":"Asia Pac Allergy"},{"key":"2026061109252054000_60.3.2102866.29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jdin.2020.10.003","article-title":"The global, regional, and national burden of fungal skin diseases in 195 countries and territories: a cross-sectional analysis from the Global Burden of Disease Study 2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int"},{"key":"2026061109252054000_60.3.2102866.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01524.x"},{"key":"2026061109252054000_60.3.2102866.31","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.3390\/ijms20194660","article-title":"The roles of sex hormones in the course of atopic dermatitis","volume":"20","author":"Kanda","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026061109252054000_60.3.2102866.32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.anai.2015.04.019","article-title":"Hormonal factors and incident asthma and allergic rhinitis during puberty in girls","volume":"115","author":"Wei","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026061109252054000_60.3.2102866.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70536-1"},{"key":"2026061109252054000_60.3.2102866.34","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12196"},{"key":"2026061109252054000_60.3.2102866.35","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3390\/jcm4051036","article-title":"Vitamin D and the development of atopic eczema","volume":"4","author":"Palmer","year":"2015","journal-title":"J Clin Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02866-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:25:33Z","timestamp":1781195133000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02866-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9,15]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1183\/13993003.02866-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02866-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]}}}